Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuesaitong Soft Capsule for Acute Coronary Syndrome After PCI
NCT06845254Phase 3Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xuesetong capsule in acute coronary syndrome (ACS) (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: Changes in thromboelastography induced by AA (R, K, alpha, MA, CI, TPI, LY30, AAYZL) at 12 weeks and Changes in thromboelastography induced by ADP (R, K, alpha, MA, CI, TPI, LY30, ADPYZL) at 12 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
xuesetong capsule
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06845254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845254.